NDA 018200 · Padagis US
Midamor
Amiloride Hydrochloride · Oral
NovelLast checked: Nov 19, 2026Latest source record: Feb 25, 2003 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1981
Oct 5, 1981
Approved uses
1
Original approval plus efficacy supplements
Registered trials
67
13 Phase 3, 5 recruiting
FAERS reports
858
731 serious, 63 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
Like other potassium-conserving agents, amiloride may cause hyperkalemia (serum potassium levels greater than 5.5 mEq per liter) which, if uncorrected, is potentially fatal. Hyperkalemia occurs commonly (about 10%) when amiloride is used without a kaliuretic diuretic. This incidence is greater in patients with renal impairment, diabetes mellitus (with or without recognized renal insufficiency), and in the elderly. When amiloride HCl is used concomitantly with a thiazide diuretic in patients without these complications, the risk of hyperkalemia is reduced to about 1-2 percent. It is thus essential to monitor serum potassium levels carefully in any patient receiving amiloride, particularly when it is first introduced, at the time of diuretic dosage adjustments, and during any illness that could affect renal function.
What it is approved for
From the label in effect Nov 11, 2026.
INDICATIONS AND USAGE Amiloride HCl is indicated as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension to: help restore normal serum potassium levels in patients who develop hypokalemia on the kaliuretic diuretic prevent development of hypokalemia in patients who would be exposed to particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride HCl has little additive diuretic or anti-hypertensive effect when added to a thiazide diuretic. Amiloride HCl should rarely be used alone. It has weak (compared with thiazides) diuretic and antihypertensive effects. Used as single agents, potassium sparing diuretics, including amiloride HCl, result in an increased risk of hyperkalemia (approximately 10% with amiloride). Amiloride HCl should be used alone only when persistent hypokalemia has been documented and only with careful titration of the dose and close monitoring of serum electrolytes.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 5, 1981 Original approval · Type 1 - New Molecular Entity
1 products under this application
- MIDAMOR · AMILORIDE HYDROCHLORIDE 5MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Amiloride" as an intervention, any sponsor and status, largest first.
- Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive PatientsPivotal-lookingStatus unknown
Chinese Academy of Medical Sciences, Fuwai HospitalAcademic, hospital or other
NCT01011660 · 13,542 participants (planned) · Start Oct 2007 · Primary completion Aug 2012
Drug: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin · For: Essential Hypertension
Sites: Beijing, China
- Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTIPivotal-lookingCompleted
Reckitt Benckiser Inc.Industry
NCT01202279 · 1,179 participants · Start Oct 2009 · Primary completion Apr 2010
Drug: Guaifenesin · For: Acute Upper Respiratory Track Infection
Sites: Mesa, Arizona; Carmichael, California; Fresno, California · 24 sites in all
- Comparison of Optimal Hypertension RegimensPivotal-lookingCompleted
Cambridge University Hospitals NHS Foundation TrustAcademic, hospital or other
NCT02847338 · 940 participants · Start Nov 2016 · Primary completion Oct 2023
Drug: Amlodipine; Lisinopril and 2 more · For: Hypertension
Sites: Cambridge, United Kingdom; Birmingham, United Kingdom; Cardiff, United Kingdom · 14 sites in all
- Hypertension Prevention in Pre-Hypertensive IndividualsPivotal-lookingCompleted
Hospital de Clinicas de Porto AlegreAcademic, hospital or other
NCT00970931 · 730 participants · Start Jul 2010 · Primary completion Sep 2014
Drug: Chlorthalidone plus amiloride; placebo · For: Pre-hypertension; Hypertension; Cardiovascular Disease
Sites: Porto Alegre, Brazil · 2 sites in all
- Diuretics and Angiotensin-Receptor Blocker Agents in Patients With Stage I HypertensionPivotal-lookingCompleted
Hospital de Clinicas de Porto AlegreAcademic, hospital or other
NCT00971165 · 655 participants · Start Jul 2010 · Primary completion Sep 2014
Drug: losartan; Chlorthalidone plus amiloride · For: Hypertension; Cardiovascular Disease
Sites: Porto Alegre, Brazil · 2 sites in all
- Phase 4 Study - Mucinex D as Adjunct TherapyPivotal-lookingCompleted
Adams Respiratory TherapeuticsIndustry
NCT00441246 · 600 participants (planned) · Start Feb 2007 · Primary completion May 2007
Drug: Mucinex D (600 mg guaifenesin and 60 mg pseudoephedrine HCl extended-release bi-layer tablets) · For: Acute Respiratory Infection; Bronchitis; Rhinosinusitis
Sites: Birmingham, Alabama; Carmichael, California; Torrance, California · 28 sites in all
- MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation TrialPivotal-lookingCompleted
University College, LondonAcademic, hospital or other
NCT01910259 · 445 participants · Start Dec 18, 2014 · Primary completion Jun 14, 2018
Drug: Amiloride; Riluzole and 2 more · For: Secondary Progressive Multiple Sclerosis
Sites: Edinburgh, United Kingdom; Glasgow, United Kingdom; Haywards Heath, United Kingdom · 13 sites in all
- Comparison of Single and Combination Diuretics in Low-Renin HypertensionPivotal-lookingStatus unknown
University of CambridgeAcademic, hospital or other
NCT02351973 · 423 participants · Start Nov 2009 · Primary completion Jul 2015
Drug: Hydrochlorthiazide; Amiloride and 1 more · For: Hypertension
Sites: Cambridge, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea69
- diarrhoea58
- nausea49
- drug interaction41
- hyperkalaemia39
- vomiting39
- malaise38
- fatigue37
- fall36
- confusional state33
- headache32
- abdominal pain29
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 6 |
| 2006 | 28 |
| 2007 | 68 |
| 2008 | 74 |
| 2009 | 75 |
| 2010 | 85 |
| 2011 | 78 |
| 2012 | 76 |
| 2013 | 13 |
| 2014 | 9 |
| 2015 | 18 |
| 2016 | 34 |
| 2017 | 9 |
| 2018 | 40 |
| 2019 | 36 |
| 2020 | 29 |
| 2021 | 20 |
| 2022 | 37 |
| 2023 | 34 |
| 2024 | 38 |
| 2025 | 26 |
| 2026 | 22 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial.
Lee CJ, Ihm SH, Shin DH, et al. · JAMA 2025 · Clinical Trial, Phase IV, Comparative Study
- Systemic pharmacological interventions for Ménière's disease.
Webster KE, Galbraith K, Harrington-Benton NA, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Amiloride and plasma-potassium.
Surveyor I, Saunders RA · Lancet 1968 · Clinical Trial, Controlled Clinical Trial
- Hypokalemia in thiazide-treated systemic hypertension.
Maronde RF, Chan LS, Vlachakis N · Am J Cardiol 1986 · Clinical Trial, Controlled Clinical Trial
- Nebulised hypertonic saline for cystic fibrosis.
Wark P, McDonald VM, Smith S · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- [Regulation of natriuresis in diabetic nephropathy].
Późniak J · Ann Acad Med Stetin 2000 · Clinical Trial, Controlled Clinical Trial
Sponsor: Padagis US
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.